ATM-deficient cancer cells and targeted therapies

Simple item page
dc.contributor.advisorLees-Miller, Susan
dc.contributor.authorJette, Nicholas Ryan
dc.contributor.committeememberNarendran, Aru
dc.contributor.committeememberSenger, Donna L.
dc.contributor.committeememberBebb, Gwyn D.
dc.date2018-11
dc.date.accessioned2018-07-12T17:24:24Z
dc.date.available2018-07-12T17:24:24Z
dc.date.issued2018-07-09
dc.description.abstractThe driving principle behind precision medicine is to specifically target genetic variations that arise in tumorigenesis while leaving normal cells unaffected. Mutations in Ataxia Telangiectasia Mutated (ATM) may offer such a therapeutic target. ATM is mutated in a variety of tumor types and these mutations can lead to a dysfunctional protein, or protein deletion. ATM is an apex signaling kinase that responds to DNA double strand breaks, playing a direct role in DNA repair as well as the initiation of signaling cascades that can lead to cell cycle arrest and apoptosis. In recent years, several studies have shown that Poly ADP-Ribose Polymerase (PARP) inhibitors effectively target ATM-deficient tumors both invitro and invivo. These studies have been limited to mantle cell lymphoma, gastric cancer, colorectal cancer and breast cancer cell lines and the mechanism of sensitivity remains unclear. Here, I show that ATM-deficient lung and pancreatic cancer cell lines are sensitive to olaparib (a PARP inhibitor) and that ATM-deficient pancreatic cancer cell lines are sensitive to the PARP inhibitor Rucaparib as well as the ATR inhibitor VE-821. Using both lung and colorectal cancer cells, I also show that olaparib induces DNA damage and that olaparib causes an accumulation of G2 phase cells in ATM-deficient cells. Since olaparib is set to become a more commonly used chemotherapeutic, these findings are both important and relevant to its use in the clinic.en_US
dc.identifier.citationJette, N. R. (2018) ATM-deficient cancer cells and targeted therapies (Doctoral thesis, University of Calgary, Calgary, Canada). Retrieved from https://prism.ucalgary.ca. doi:10.11575/PRISM/32359en_US
dc.identifier.doihttp://dx.doi.org/10.11575/PRISM/32359
dc.identifier.urihttp://hdl.handle.net/1880/107137
dc.language.isoeng
dc.publisher.facultyGraduate Studies
dc.publisher.facultyScience
dc.publisher.institutionUniversity of Calgaryen
dc.publisher.placeCalgaryen
dc.rightsUniversity of Calgary graduate students retain copyright ownership and moral rights for their thesis. You may use this material in any way that is permitted by the Copyright Act or through licensing that has been assigned to the document. For uses that are not allowable under copyright legislation or licensing, you are required to seek permission.
dc.subjectATM PARP Olaparib colorectal lung pancreatic
dc.subject.classificationOncologyen_US
dc.subject.classificationBiochemistryen_US
dc.titleATM-deficient cancer cells and targeted therapies
dc.typedoctoral thesis
thesis.degree.disciplineMedical Science
thesis.degree.grantorUniversity of Calgary
thesis.degree.nameDoctor of Philosophy (PhD)
ucalgary.item.requestcopytrue
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ucalgary_2018_jette_nicholas.pdf
Size:
12.67 MB
Format:
Adobe Portable Document Format
Description:
Thesis
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.74 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Open Theses and Dissertations